Skip to main content
Jianying Xi on Muck Rack

Jianying Xi

As seen in: Frontiers in Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jianying

Contact Jianying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China

|
By Yafang Xu, Ling Feng, Mingjie Zhang, Jing Zhou, Hongwei Xiao, Rui Wang, Yueyue He, Qian Jiang, Jianyu Peng, Hong Ru Chen, Hongyu Zhou, Dingxian He, Sushan Luo, Jianying Xi, Jie Song, Chong Yan, Jiahong Lu, Chongbo Zhao, Yuwen Ni
| Frontiers in Immunology
Abstract Background: Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that imposes a substantial disease burden in China. As novel therapeutic options emerge, understanding patient preferences has become essential for treatment decision-making. This study aimed to assess treatment preferences and willingness to pay (WTP) among Chinese gMG patients. Methods: This multicenter, cross-sectional survey was conducted from March to August 2025 among patients with gMG in China.
Open in Who Shared Issue with article?

Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study

|
By Dingxian He, Hongxi Chen, Huahua Zhong, Nana Zhang, Chong Yan, Jie Song, Sushan Luo, Chongbo Zhao, Hongyu Zhou, Jianying Xi
| Frontiers in Immunology
Abstract Background: Predicting exacerbation risk in clinically treated patients with myasthenia gravis (MG) is essential for personalised intervention with neurotherapies. This study investigated whether dynamic monitoring of anti-acetylcholine receptor antibody (AChR-ab) levels could predict exacerbation in MG patients following minimal symptom expression (MSE), and developed a validated model for risk stratification to inform treatment decisions.
Open in Who Shared Issue with article?
See all 2 articles